A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
Launched by AGOURON PHARMACEUTICALS · Aug 30, 2001
Trial Information
Current as of March 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • HIV infection.
- • Newly diagnosed or first progression of CMV retinitis.
- • Exclusion Criteria
- Prior Medication:
- Excluded:
- • Prior therapy (or less than 2 weeks) with protease inhibitor other than saquinavir.
About Agouron Pharmaceuticals
Agouron Pharmaceuticals is a biopharmaceutical company dedicated to advancing innovative therapies for the treatment of serious medical conditions. With a strong focus on research and development, Agouron leverages cutting-edge science and technology to discover and optimize novel drug candidates. The company is committed to improving patient outcomes through rigorous clinical trials and collaborations with healthcare professionals. By prioritizing safety and efficacy, Agouron aims to deliver transformative solutions that address unmet medical needs and enhance the quality of life for patients around the world.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Torrance, California, United States
Chicago, Illinois, United States
Los Angeles, California, United States
Galveston, Texas, United States
Orange, California, United States
San Diego, California, United States
Washington, District Of Columbia, United States
Houston, Texas, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials